A comparison of normal and leukemic stem cell biology in chronic myeloid leukemia

Jorgensen, H.G. and Holyoake, T.L. (2001) A comparison of normal and leukemic stem cell biology in chronic myeloid leukemia. Hematological Oncology, 19(3), pp. 89-106. (doi: 10.1002/hon.667.abs)

Full text not currently available from Enlighten.


Chronic Myeloid Leukemia (CML), a myeloproliferative disease of stem cell origin, is characterized by the presence of the Philadelphia (Ph) chromosome and the <i>bcr-abl</i> oncogene. The BCR-ABL fusion gene product, thought to be causative in CML, has multiple effects on diverse cell functions such as growth, differentiation and turnover as well as adhesion and apoptosis. Persistent Ph-negative progenitors co-exist with leukemic cells, both in the marrow and blood of patients, in the early chronic phase or the disease. Despite accumulating knowledge or hemopoiesis and the disease process, CML remains incurable with conventional chemotherapy. Nonetheless, with the efficacy of the ABL tyrosine kinase inhibitor STI-571 (signal transduction inhibitor 571) as a novel therapy in CML recently being realized in clinical trials, it is therefore timely to review our current understanding of the cell biology of this fascinating disease.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Holyoake, Professor Tessa and Jorgensen, Dr Heather
Authors: Jorgensen, H.G., and Holyoake, T.L.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Hematological Oncology

University Staff: Request a correction | Enlighten Editors: Update this record